Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to CU1994007ApriorityCriticalpatent/CU22414A1/en
Publication of CU22414A1publicationCriticalpatent/CU22414A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Abstract
ESTA INVENCION SE RELACIONA CON LAS RAMAS DE LA SALUD HUMANA Y ANIMAL, PARA EL TRATAMIENTO DE VARIOS TIPOS DE NEOPLASIAS. EL OBJETIVO TECNICO DE DICHA SOLUCION ES OBTENER UN PREPARADO FARMACEUTICO A PARTIR DE ALACRAN (RHOPALURUS JUNCEUS) QUE PRESENTA EFECTO ANTITUMORAL. LA ESENCIA DE LA INVENCION RADICA EN LA PREPARACION DE UN PRODUCTO FARMACEUTICO A PARTIR DEL ALACRAN, QUE TIENE ENTRE SUS COMPONENTES: CONCENTRACION DE PROTEINAS; ACTIVIDAD PROTEOLITICA: ACIDA NEUTRAL Y ALCALINA, Y ALCALINA (NEGATIVA): ACTIVIDAD INHIBIDORA DE PROTEASAS: FRENTE A PROTEASA DEL TIPO SERINO 18 UNIDADES BAEE.ML-1; FRENTE A PROTEASA DEL TIPO CISTEINO: 4 UNIDADES BAEE.ML 1, ACTIVIDAD FOSFOLIPASICA TIPO A2 1, 0,15A10-3; ACTIVIDAD HEMOLITICA (NEGATIVA). DICHO PRODUCTO PUEDE APLICARSE EN LA ESFERA DE LA ELABORACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE DIFERENTES TIPOS DE NEOPLASIAS.\!THIS INVENTION IS RELATED TO THE BRANCHES OF HUMAN AND ANIMAL HEALTH, FOR THE TREATMENT OF SEVERAL TYPES OF NEOPLASMS. THE TECHNICAL OBJECTIVE OF SUCH SOLUTION IS TO OBTAIN A PHARMACEUTICAL PREPARATION FROM ALACRAN (RHOPALURUS JUNCEUS) THAT PRESENTS ANTI-TUMORAL EFFECT. THE ESSENCE OF THE INVENTION IS IN THE PREPARATION OF A PHARMACEUTICAL PRODUCT FROM ALACRAN, WHICH HAS BETWEEN ITS COMPONENTS: PROTEIN CONCENTRATION; PROTEOLYTIC ACTIVITY: NEUTRAL AND ALKALINE ACID, AND ALKALINE (NEGATIVE): PROTEASE INHIBITING ACTIVITY: AGAINST SERINE TYPE PROTEASE 18 UNITS BAEE.ML-1; AGAINST PROTEASE OF THE CYSTEINE TYPE: 4 UNITS BAEE.ML 1, PHOSPHOLIPASIC ACTIVITY TYPE A2 1, 0.15A10-3; HEMOLYTIC ACTIVITY (NEGATIVE). SUCH PRODUCT MAY BE APPLIED IN THE FIELD OF PREPARING MEDICINES FOR THE TREATMENT OF DIFFERENT TYPES OF NEOPLASMS. \!
Medium-chain length fatty acids, glycerides and analogues as neutrophile survival and activation factors and pharmaceutical compositions containing them
AMIDAS OF ANTRANILIC ACIDS WITH SIDE CHAIN OF HETEROARILSULFONILO, PROCEDURE FOR THEIR PREPARATION, ITS EMPLOYMENT AS A MEDICINAL OR DIAGNOSTIC AGENT, AS WELL AS PHARMACEUTICAL PREPARATIONS CONTAINING THEM
Nutritional or therapeutic composition usable for treating mammals to increase immune activity and method of treating a mammal to increase the concentration of glutathione in the tissue in said mammal
CHROMANS SUBSTITUTED WITH SULFONAMIDE, PROCEDURE FOR THEIR PREPARATION, ITS USE AS A MEDICINAL PRODUCT, AS WELL AS PHARMACEUTICAL PREPARATIONS CONTAINING THEM.